PepGen Inc
PEPG4.210USD
-0.330-7.27%
Fechamento 11/06, 16:00（ET）Cotações atrasadas em 15 min
138.09MValor de mercado
PerdaP/L TTM
Mais detalhes de PepGen Inc Empresa
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Informações de PepGen Inc
Código da empresaPEPG
Nome da EmpresaPepGen Inc
Data de listagemMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Número de funcionários81
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 06
Endereço245 Main St, 2nd Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone17034568000
Sitehttps://pepgen.com
Código da empresaPEPG
Data de listagemMay 06, 2022
CEODr. James G. Mcarthur, Ph.D.
Executivos da empresa PepGen Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Point72 Asset Management, L.P.
4.01%
Millennium Management LLC
2.20%
Outro
52.32%
Investidores
Investidores
Proporção
RA Capital Management, LP
29.19%
Oxford Science Enterprises PLC
7.21%
Viking Global Investors LP
5.07%
Point72 Asset Management, L.P.
4.01%
Millennium Management LLC
2.20%
Outro
52.32%
Tipos de investidores
Investidores
Proporção
Venture Capital
36.40%
Hedge Fund
12.46%
Investment Advisor/Hedge Fund
5.92%
Investment Advisor
2.67%
Sovereign Wealth Fund
1.81%
Research Firm
0.25%
Individual Investor
0.13%
Outro
40.36%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
157
40.91M
59.52%
+1.09M
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
20.06M
29.19%
+9.38M
+87.70%
Sep 26, 2025
Oxford Science Enterprises PLC
4.96M
7.21%
+200.00K
+4.21%
Sep 30, 2025
Viking Global Investors LP
3.48M
5.07%
+2.00M
+134.91%
Sep 26, 2025
Point72 Asset Management, L.P.
2.76M
4.01%
+83.23K
+3.11%
Jun 30, 2025
Millennium Management LLC
1.51M
2.2%
+476.18K
+46.10%
Jun 30, 2025
Adage Capital Management, L.P.
1.35M
1.96%
--
--
Jun 30, 2025
Qatar Investment Authority
1.24M
1.81%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
937.02K
1.36%
+37.29K
+4.14%
Jun 30, 2025
Laurion Capital Management LP
810.76K
1.18%
--
--
Jun 30, 2025
Woodline Partners LP
691.53K
1.01%
-89.37K
-11.44%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 17 horas
Atualizado em: há 17 horas
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Micro-Cap ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Ver Mais
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
iShares Micro-Cap ETF
Proporção0.02%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
iShares Biotechnology ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
